瘤内注射核素标记混合抗体治疗肝癌的实验研究

Experimental studies of treatment of the liver cancer by intratumoral injection of 131I-labeled multiple monoclonal antibodies

目的 为临床应用混合抗体进行瘤内注射放射免疫治疗提供实验依据。方法 在裸鼠荷人肝癌2.2.15移植瘤生长至1 cm时，瘤内分别或同时注射131I标记的抗癌胚蛋白（AFP）单克隆抗体（131I -AFP-IT）和131I标记抗乙型肝炎表面抗原单克隆抗体S102（131I- S102-IT），治疗后行SPECT显像观察标记抗体在肿瘤内的浓聚，并进行疗效观察。 结果 发现两种标记抗体联合治疗组肿瘤抑制率为76.5%，明显高于131I -AFP-IT组的53.1%及131I- S102-IT组的47.3%，抗体在肿瘤内的浓聚也明显高于单独应用组。结论 多种抗体混合应用瘤内注射放射免疫治疗可增加标记抗体在肿瘤内的浓聚，并能提高放射免疫治疗的疗效。

Objective To provide experimental basis for radioimmunotherapy of tumors by intratumoral infection of 131I-labeled multiple monoclonal antibodies. Methods Nude mice bearing subcutaneous human liver carcer xenografts were treated by intratumoral injection of 131I-labeled anti-AFP (a-fetoprotein) monoclonal antibody (131I-AFP) and/or 131I-labeled anti-HbsAg monoclonal antibody S102 (131I- S102). The alteration of the tumor size was observed and the radioactivity concentrations in the tumor, liver, blood and kidney were measured. Result It was found that the inhibition rate of the tumor in the group treated with 131I- AFP and 131I- S102 (76.5%) was higher than that in the group treated with 131I- S102 (47.3%) or 131I- AFP (53.1%) alone. The radioactivity concentration ratio of tumor to normal tissue (T/NT) in the group treated with 131I-AFP and 131I- S102 was higher than that in the group treated with 131I- S102 or 131I- AFP alone. Conclusion Intratumoral injection of 131I-labeled multiple monoclonal antibodies can increase the concentration of 131I-labeled monoclonal antibodies in tumor and enhance the efficacy of the radioimmunotherapy .